<DOC>
	<DOCNO>NCT00169533</DOCNO>
	<brief_summary>The EGF19060 study rollover study evaluate long term safety lapatinib provide lapatinib patient positive response previous lapatinib study lapatinib available pending FDA approval .</brief_summary>
	<brief_title>Rollover Study Of Lapatinib In Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Currently receive clinical benefit define CR , PR SD treatment lapatinib participation Phase I study lapatinib either monotherapy part combination regimen . Ability understand provide write informed consent participate trial . Is male female . Female male subject agree protocol specific birth control measure Permanent discontinuation lapatinib previous study due intolerance treatment failure . Is pregnant lactate female . Is consider medically unfit study investigator result medical interview , physical exam , screen investigation . Currently receive treatment medication list prohibited medication list ( see Section 7.2 ) . Has Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system . Has leave ventricular ejection fraction ( LVEF ) &lt; 40 % base MUGA ECHO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerate lapatinib</keyword>
	<keyword>Lapatinib</keyword>
</DOC>